Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol.

[1]  F. Fezza,et al.  New insights into endocannabinoid degradation and its therapeutic potential. , 2006, Mini reviews in medicinal chemistry.

[2]  D. Cota,et al.  The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.

[3]  B. Scatton,et al.  The Canadian Consortium for the Investigation of Cannabinoids in Human Therapeutics , 2022 .

[4]  M. Maccarrone.  Fatty acid amide hydrolase: a potential target for next generation therapeutics. , 2006, Current pharmaceutical design.

[5]  M. Gonthier,et al.  Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes , 2006, Histochemistry and Cell Biology.

[6]  M. Cascio,et al.  Endocannabinoid metabolic pathways and enzymes. , 2005, Current drug targets. CNS and neurological disorders.

[7]  K. Mackie,et al.  Identification functional characterization of brainstem cannabinoid CB2 receptors. , 2022 .

[8]  B. Barboni,et al.  Characterization of the endocannabinoid system in boar spermatozoa and implications for sperm capacitation and acrosome reaction , 2005, Journal of Cell Science.

[9]  Arya M. Sharma,et al.  Activation of the peripheral endocannabinoid system in human obesity. , 2005, Diabetes.

[10]  P. Casellas,et al.  Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. , 2005, European journal of pharmacology.

[11]  A. Gerber,et al.  Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH) , 2005, International Journal of Obesity.

[12]  B. Cravatt,et al.  Structure and function of fatty acid amide hydrolase. , 2005, Annual review of biochemistry.

[13]  M. Maj,et al.  Blood Levels of the Endocannabinoid Anandamide are Increased in Anorexia Nervosa and in Binge-Eating Disorder, but not in Bulimia Nervosa , 2005, Neuropsychopharmacology.

[14]  K. Mackie,et al.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.

[15]  V. Marzo,et al.  Endocannabinoid control of food intake and energy balance , 2005, Nature Neuroscience.

[16]  A. Rissanen,et al.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.

[17]  M. Kosteljanetz,et al.  Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non‐tumour brain tissue , 2005, Journal of neurochemistry.

[18]  F. Fezza,et al.  Radiochromatographic assay of N-acyl-phosphatidylethanolamine-specific phospholipase D activity. , 2005, Analytical biochemistry.

[19]  M. Stock,et al.  Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice , 2005, International Journal of Obesity.

[20]  J. Herbert,et al.  The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile , 2005, Diabetes, obesity & metabolism.

[21]  M. Korbonits,et al.  The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin , 2004, British journal of pharmacology.

[22]  V. Large,et al.  Metabolism of lipids in human white adipocyte. , 2004, Diabetes & metabolism.

[23]  V. Marzo,et al.  Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. , 2004 .

[24]  F. Fezza,et al.  Endocannabinoids and their involvement in the neurovascular system. , 2004, Current neurovascular research.

[25]  N. Ueda,et al.  Molecular Characterization of a Phospholipase D Generating Anandamide and Its Congeners* , 2004, Journal of Biological Chemistry.

[26]  Gareth Williams,et al.  Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain , 2003, The Journal of cell biology.

[27]  C. Hillard,et al.  Cellular accumulation of anandamide: consensus and controversy , 2003, British journal of pharmacology.

[28]  C. Newton,et al.  The cannabinoid system and immune modulation , 2003, Journal of leukocyte biology.

[29]  M. Guzmán,et al.  Cannabinoids: potential anticancer agents , 2003, Nature Reviews Cancer.

[30]  M. Maccarrone,et al.  The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis , 2003, Cell Death and Differentiation.

[31]  N. Stella,et al.  Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors. , 2003, European journal of pharmacology.

[32]  T. Horvath.  Endocannabinoids and the regulation of body fat: the smoke is clearing. , 2003, The Journal of clinical investigation.

[33]  C. Flachskamm,et al.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. , 2003, The Journal of clinical investigation.

[34]  A. Finazzi-Agro’,et al.  Leptin Activates the Anandamide Hydrolase Promoter in Human T Lymphocytes through STAT3* , 2003, The Journal of Biological Chemistry.

[35]  Brian Vastag,et al.  Experimental drugs take aim at obesity. , 2003, JAMA.

[36]  P. Soubrié,et al.  The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. , 2003, Molecular pharmacology.

[37]  A. Howlett.  The cannabinoid receptors. , 2002, Prostaglandins & other lipid mediators.

[38]  E. Berry,et al.  Tetrahydrocannabinol and endocannabinoids in feeding and appetite. , 2002, Pharmacology & therapeutics.

[39]  T. Freund,et al.  Brain monoglyceride lipase participating in endocannabinoid inactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Yamakuchi,et al.  Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. , 2001, Analytical biochemistry.

[41]  A. Finazzi-Agro’,et al.  The Activity of Anandamide at Vanilloid VR1 Receptors Requires Facilitated Transport across the Cell Membrane and Is Limited by Intracellular Metabolism* , 2001, The Journal of Biological Chemistry.

[42]  R. Palmiter,et al.  Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.

[43]  V. Di Marzo,et al.  Structure‐activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens , 2001, British journal of pharmacology.

[44]  S. Dey,et al.  Ligand-receptor signaling with endocannabinoids in preimplantation embryo development and implantation. , 2000, Chemistry and physics of lipids.

[45]  A. Makriyannis,et al.  Functional CB1 cannabinoid receptors in human vascular endothelial cells. , 2000, The Biochemical journal.

[46]  Gerald Maguire,et al.  Expression of CB2 cannabinoid receptor mRNA in adult rat retina , 2000, Visual Neuroscience.

[47]  D. Julius,et al.  Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide , 1999, Nature.

[48]  P. Blumberg,et al.  Vanilloid (Capsaicin) receptors and mechanisms. , 1999, Pharmacological reviews.

[49]  J. Shannon,et al.  Expression of a brain-type cannabinoid receptor (CB1) in alveolar Type II cells in the lung: regulation by hydrocortisone. , 1997, European journal of pharmacology.

[50]  P. C. Schmid,et al.  Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. , 1983, The Journal of biological chemistry.

[51]  R. Mechoulam,et al.  The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. , 1971, Journal of the American Chemical Society.

[52]  F. Fezza,et al.  The anandamide membrane transporter and the therapeutic implications of its inhibition , 2005 .

[53]  R. Pertwee.  Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.